Clinical trial · no report yet · Phase 3
Orca-T
Precision-T: A Randomized Study of Orca-T in Recipients Undergoing Allogeneic Transplantation for Hematologic Malignancies
- NCT05316701 ↗
- Active, not recruiting
- Orca Biosystems, Inc.
- Deep
We haven't built a report for this trial yet. This page shows the registry record and the public commentary we found that names the trial. A report reads that commentary and sets out what clinicians said about the trial, each point linked to its source. How reports are made.
Preliminary discovery
Commentary in our index that names this trial so far
Podcasts, YouTube videos and X posts we have indexed. A report screens them, searches for more and cites what clinicians said when it is built, so final coverage is set at build.
| Channel | Found | |
|---|---|---|
| YouTube | 10 | |
| Podcasts | 7 | |
| X threads | 6 | |
| Bluesky threads | 1 |
The trial
ClinicalTrials.gov- Official title
- A Randomized Phase III Trial of Patients With Advanced Hematologic Malignancies Undergoing Allogeneic Hematopoietic Cell Transplantation With Either Orca-T, a T-cell-Depleted Graft With Additional Infusion of Conventional T Cells and Regulatory T Cells, or Standard-of-Care Allogeneic Graft
- Phase
- Phase 3
- Status
- Active, not recruiting
- Conditions
- Acute Myeloid Leukemia; Acute Lymphoid Leukemia; Mixed Phenotype Acute Leukemia; Undifferentiated Leukemia; Myelodysplastic Syndrome; Acute Leukemia; Therapy-Related Myelodysplastic Syndrome
- Interventions
- Orca-T; Standard-of-Care
- Arms
- Orca-T · Experimental
- Standard of Care alloHCT Control · Active comparator
- Enrollment
- 187
- Primary outcomes
- Event-free at 12 Months for Moderate or Severe Chronic Graft-versus-Host-Disease-free Survival (cGFS) Per Endpoint Adjudication Committee (EAC)
- Sponsor
- Orca Biosystems, Inc.
- Start
- Jun 21, 2022
- Primary completion
- Jul 15, 2024
- Results posted
- Yes
- Registry record
- NCT05316701 · updated Mar 4, 2026
Publications
linked from the registry- Meyer EH, Salhotra A, Gandhi AP, Pantin J, Patel SS, Hoeg RT, Gomez-Arteaga A, Faramand R, Tamari R, Waller EK, Kosuri S, Jimenez Jimenez AM, Holter-Chakrabarty J, Dholaria B, Chen YB, Hamilton BK, Magenau J, Eghtedar A, Murray JM, Pavlova A, Fernhoff NB, McClellan JS, Killian MS, Li A, Negrin RS, Oliai C. Orca-T vs allogeneic hematopoietic stem cell transplantation (Precision-T): a multicenter, randomized phase 3 trial. Blood. 2026 Mar 12;147(11):1168-1177. doi: 10.1182/blood.2025031313. PubMed 41385341
- Faramand R, McClellan JS, Pavlova A, Manghani R, Blank A, Saeedian M, Yadav S, Perales MA. Cost-effectiveness of Orca-T vs allo-HCT with conventional GVHD prophylaxis for the treatment of advanced hematologic malignancies in the United States. J Med Econ. 2026 Dec;29(1):2386-2405. doi: 10.1080/13696998.2026.2732644. Epub 2026 Sep 29. PubMed 42806776